Drug Trial Radar · NCT02503657
Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Mar 9, 2016
Primary completion
Dec 7, 2020
Study completion Mar 15, 2022
Sponsor
- Lead sponsor
- MediciNovaIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in patients diagnosed with moderate to severe idiopathic pulmonary fibrosis (IPF). Participants were randomly assigned to receive MN-001 or matching placebo twice daily over a 26-week period. A total of 15 participants were enrolled.
Conditions
- Idiopathic Pulmonary Fibrosis
- IPF
Interventions
MN-001Drug
A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
PlaceboDrug
Excipients of MN-001/tipelukast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Forced Vital Capacity for 26 WeeksTime frame: Baseline and Week 26 at the end of Double-blind treatment period.
- Percent Change in Forced Vital Capacity From Baseline to Week 26Time frame: Baseline, and Week 26 at the endpoint of the Double-blind treatment period.
- Absolute Change From Baseline in Forced Vital Capacity (% Predicted)Time frame: Baseline and Week 26 at the end of Double-blind treatment period.
- Relative Change From Baseline in Percent Predicted Forced Vital Capacity From Baseline to Week 26Time frame: Baseline and Week 26 at the end of Double-blind treatment period.
- Semiannual Rate of Decline of Disease Activity Based on Forced Vital CapacityTime frame: Baseline and Week 26 at the end of Double-blind treatment period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Penn State University College of Medicine, Milton S. Hershey Medical Center
Hershey, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.